Chemotherapy of malignant fibrous histiocytoma of bone

Background: Malignant fibrous histiocytoma of bone (MFHB) is a rare tumour with a 3 year survival of 30%-40% when treated with surgery alone. A small number of patients have previously been treated with pre-operative chemotherapy and responses observed. The aim of the present study was to further de...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology 1993-05, Vol.4 (5), p.409-415
Main Authors: Earl, H. M., Pringle, J., Kemp, H., Morittu, L., Miles, D., Souhami, R.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bone Neoplasms - drug therapy
Bone Neoplasms - pathology
Bone Neoplasms - surgery
bone sarcoma
Chemotherapy
Chemotherapy, Adjuvant
Female
Histiocytoma, Benign Fibrous - drug therapy
Histiocytoma, Benign Fibrous - pathology
Histiocytoma, Benign Fibrous - surgery
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Preoperative Care
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Malignant fibrous histiocytoma of bone (MFHB) is a rare tumour with a 3 year survival of 30%-40% when treated with surgery alone. A small number of patients have previously been treated with pre-operative chemotherapy and responses observed. The aim of the present study was to further determine the response of MFHB to pre-operative chemotherapy. Patients and methods: A non-randomised study of 18 patients with MFHB. Twelve had localised disease and 6 had pulmonary metastases. In 14 patients pre-operative treatment consisted of methotrexate 8 g/m2 on day 1, ifosfamide 3 g/m2 and doxorubicin 60 mg/m2 on day 10. This regimen was given twice and twice post-operatively. A further 4 patients received cisplatin 100 mg/m2 on day ] and doxorubicin 25 mg/m2 on days 1, 2, 3. Three cycles were given preand post-operatively. Results: 15 patients had surgery after chemotherapy. Tumour necrosis was present in all resection specimens and ranged from 50%–100%. 7/15 had >90% necrosis. Disease free survival is 82% for those patients with a greater than 2 year follow-up. Conclusion: This study confirms previous reports that MFHB is a chemosensitive tumour. In view of its rarity collaborative trials are needed to establish the optimum drug treatment including drug selection dose and duration.
ISSN:0923-7534
1569-8041
DOI:10.1093/oxfordjournals.annonc.a058521